ABC transporter expression in hematopoietic stem cells and the role in AML drug resistance

Variability in responsiveness to lovastatin of the primitive CD34+ AML subfraction compared to normal CD34+ cells

“…Three groups are demonstrated in a-f. Two AML patient groups (normal responders (n=13) and abnormal responders (n=4); in total, n=17) and a normal CD34 +/− group (n=7) are shown. SEM are indicated might provide additional information especially regarding the primitive CD34 + AML cells that are responsible for the ongoing in vivo propagation [19,20]. By studying two different subpopulations of AML cells (primitive CD34 + cells and more mature CD34 − cells), we were able to demonstrate a significant difference in lovastatin susceptibility.…”

Flow cytometry‐based assessment of mitoxantrone efflux from leukemic blasts varies with response to induction chemotherapy in acute myeloid leukemia

“…Although several ABC transporter genes (ABCA2, ABCA3, ABCB1, ABCB4, ABCB5, ABCB11, ABCC1$6, and ABCG2) are associated with chemotherapeutic drug resistance, MDR1 and BCRP1 are the principal multidrug resistance (MDR) proteins that have been identified in AML blasts including leukemia stem cells (LSCs) (47)(48)(49)(50)(51). In our own previous work QRT-PCR was used to measure expression of all 49 ABC transporters thus far identified in man in AML blasts from newly diagnosed Table 10 The MFIR Predicts Overall Survival (OS) !…”

Cholesterol and Triglycerides Metabolism Disorder in Malignant Hemopathies

“…It was observed that when some ABC transporters have a high expression in leukemia cells, the prognosis of patients with AML is reserved as the response to treatment is inadequate. (de Jonge-Peeters et al, 2007) The most studied transporter is the P-glycoprotein transporter (P-gp) -an ABC transporter responsible for unidirectional transmembrane translocation of the substrate (Gayet et al, 2005). P-gp is frequently involved in the emergence of multidrug resistance during chemotherapy (Shu & Liu, 2007).…”